Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19–22, 2001, Philadelphia, PA, USA
ABSTRACT A consensus conference on the role of sentinel node biopsy in breast cancer was held in Philadelphia in April 2001. The participants included many highly respected American and European investigators in this area. This report summarizes the deliberations of the group and promotes its current guidelines for the integration of this new technique into contemporary clinical practice.
SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: The aim of this study was to retrospectively determine the accuracy and feasibility of using (99m)Tc-dextran (DX) lymphoscintigraphy for the localization of sentinel lymph nodes (SLNs) in breast cancer patients. The relevant factors affecting lymphoscintigraphy were also investigated. In this study, 235 breast cancer patients underwent (99m)Tc-DX lymphoscintigraphic imaging and examination by a γ-probe method in combination with blue dye staining to detect SLNs. The detection results were considered in combination with rapid frozen pathology results to determine whether SLN metastasis was positive or negative. SLNs were identified in 191 patients by γ-probe detection among the 202 patients that tested positive by lymphoscintigraphic imaging, a coincidence rate of 94.6%. This suggested that lymph node metastasis had occurred and could be detected using lymphoscintigraphy. The axillary status of the breast cancer patients was also predicted using lymphoscintigraphy and the false-negative rate, sensitivity, specificity and positive predictive value were 13.3% (4/30), 90.7% (39/43), 23.4% (45/192) and 13.5% (21/155), respectively. The age of the patient, menstrual status, tumor location, tumor size, pathological type, preoperative biopsy and neoadjuvant chemotherapy were unrelated to the success of lymphoscintigraphy (P>0.05). (99m)Tc-DX lymphoscintigraphy is able to exactly determine the location of SLN in breast cancer patients, and can be used for guiding γ-probe methods and sentinel lymph node biopsy.Experimental and therapeutic medicine 01/2015; 9(1):112-116. DOI:10.3892/etm.2014.2048 · 0.94 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Objective This study evaluated the use of TachoSil as an adjunctive therapy for reducing axillary lymphocele formation. Methods Eighty-six patients diagnosed with breast cancer N+ treated with axillary lymphadenectomy received a TachoSil patch in the axillary wound. Using a database of patients without placing a hemostatic patch, we applied a matched case-control in a 1-to-2 fashion. Multiple and logistic regression analyses were used to evaluate postoperative results. Results Patient group with TachoSil showed a significantly lower drainage volume (p<0.001) and the length of stay was significantly shorter (p<0.001). The number of patients with evacuative punctures were 24.5% in the group with patch versus 51.2% in control group (p<0.001). In multivariate analysis, the use of TachoSil was a significant predictor of reduction axillary drainage volume (p<0.001), mean length of hospital stay (p=0.001), and number of evacuative punctures of lymphocele (OR 0.264, 95% CI 0.144 to 0.484, p<0.001). Conclusions Use of TachoSil in axillary lymphadenectomy may be a safe and useful treatment option for reducing axillary drainage volume, incidence of symptomatic lymphocele and hospital stay.The American Journal of Surgery 11/2014; 208(5). DOI:10.1016/j.amjsurg.2013.12.041 · 2.41 Impact Factor